Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IBRX ImmunityBio Inc
- Stocks
- Healthcare
- NASDAQ: IBRX
Price (delayed)
$2.09
Market cap
$1.78B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$2.43B
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer
Highlights
The company's gross profit has surged by 101% QoQ
ImmunityBio's revenue has surged by 101% QoQ
ImmunityBio's quick ratio has decreased by 40% YoY but it has increased by 25% from the previous quarter
Key stats
What are the main financial stats of IBRX
Market
Valuations
Earnings
Shares outstanding
853.44M
Market cap
$1.78B
Enterprise value
$2.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
98.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
164.72
Revenue
$14.75M
Gross profit
$14.75M
Operating income
-$344.18M
Net income
-$413.56M
EBIT
-$259.24M
EBITDA
-$235.93M
Free cash flow
-$398.12M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.62
Free cash flow per share
-$0.57
Book value per share
-$0.7
Revenue per share
$0.02
TBVPS
$0.53
Total assets
$382.93M
Total liabilities
$871.06M
Debt
$788.57M
Equity
-$489.1M
Working capital
$129.64M
Debt to equity
-1.61
Current ratio
3.36
Quick ratio
2.77
Net debt/EBITDA
-2.73
Margins
Efficiency
Dividend
EBITDA margin
-1,600%
Gross margin
100%
Net margin
-2,804.8%
Operating margin
-2,334.2%
Return on assets
-103.9%
Return on equity
N/A
Return on invested capital
-23.2%
Return on capital employed
-79%
Return on sales
-1,758.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBRX stock price
How has the ImmunityBio stock price performed over time
Intraday
10.58%
1 week
-16.06%
1 month
-13.64%
1 year
-73.61%
YTD
-18.36%
QTD
-30.56%
Financial performance
How have ImmunityBio's revenue and profit performed over time
Revenue
$14.75M
Gross profit
$14.75M
Operating income
-$344.18M
Net income
-$413.56M
Gross margin
100%
Net margin
-2,804.8%
The company's gross profit has surged by 101% QoQ
ImmunityBio's revenue has surged by 101% QoQ
The net margin has surged by 97% year-on-year and by 65% since the previous quarter
ImmunityBio's operating margin has soared by 96% YoY and by 52% from the previous quarter
Price vs fundamentals
How does IBRX's price correlate with its fundamentals
Growth
What is ImmunityBio's growth rate over time
Valuation
What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
98.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
164.72
ImmunityBio's EPS has increased by 49% YoY and by 34% QoQ
ImmunityBio's equity has increased by 34% QoQ and by 17% YoY
ImmunityBio's revenue has surged by 101% QoQ
The P/S is 98% less than the 5-year quarterly average of 4872.1 and 97% less than the last 4 quarters average of 3939.3
Efficiency
How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 98% YoY and by 71% QoQ
The company's return on invested capital has surged by 64% YoY and by 40% QoQ
IBRX's return on assets is up by 30% year-on-year and by 24% since the previous quarter
Dividends
What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBRX.
Financial health
How did ImmunityBio financials performed over time
The total assets is 56% less than the total liabilities
ImmunityBio's quick ratio has decreased by 40% YoY but it has increased by 25% from the previous quarter
The current ratio has decreased by 33% YoY but it has increased by 25% from the previous quarter
ImmunityBio's equity has increased by 34% QoQ and by 17% YoY
The debt has declined by 22% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.